Technology | March 17, 2010

FFR System Enhanced, Now Integrated With Siemens

The wireless PressureWire Aeris FFR measurement system.

March 17, 2010 – A new agreement with Siemens Medical Solutions expands access to the wireless PressureWire Aeris fractional flow reserve (FFR) measurement technology. St. Jude Medical also announced several updates to its PressureWire platform this week at ACC 2010.

The new marketing agreement integrates the wireless FFR system with Siemen’s AXIOM Sensis XP cath lab hemodynamic recording system to immediately display, measure and save FFR data. This documents the severity of coronary lesions, together with other procedural data and angiographic imagery. The wireless technology of the PressureWire Aeris also eliminates cables crossing the sterile field.

Because of this new agreement with Siemens, and existing compatibility with other recording systems including the GE Mac-Lab Hemodynamic Recording System, Mennen Horizon XVu and the McKesson Horizon Cardiology Hemo solution, the PressureWire Aeris technology can be used in the majority of cardiac cath labs for wireless integrated FFR measurement utilizing existing hardware.

The new version of the PressureWire Certus FFR wire was also introduced at ACC. It includes modifications to design and functionality that will provide physicians with more controlled handling and versatility. It is the only guide wire on the market to offer in one wire the combined measurement of pressure and temperature, which enables calculations of FFR, coronary flow reserve (CFR) and an index of microcirculatory resistance (IMR).

The PressureWire Certus was the only FFR measurement system used in the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which found both superior clinical outcomes and reduced healthcare costs in patients whose treatment was based on FFR.

For more information: sjm.com

Related Content

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

News | FFR Technologies | July 09, 2020
July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II
The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

Feature | FFR Technologies | July 07, 2020 | Dave Fornell, Editor
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether...
In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image.

In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image. 

Feature | FFR Technologies | August 05, 2019 | Dave Fornell and Greg Freiherr
New technologies have been developed that may replace the traditional pressure wires and adenosine to assess the...
First Prospective Registry Confirms FFR Impacts CAD Treatment Plans
News | FFR Technologies | June 17, 2019
A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans...
One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

Technology | FFR Technologies | March 06, 2019
March 5, 2019 –  The U.S.
CathWorks FFRangio System Receives U.S. FDA Clearance
Technology | FFR Technologies | December 21, 2018
CathWorks announced that its FFRangio System received U.S. Food  and Drug Administration (FDA) 510(k) clearance. The...